ArticleJournal of fungi (Basel, Switzerland)2022
Silver Nanoparticles: A Promising Antifungal Agent against the Growth and Biofilm Formation of the Emergent
Article in Journal of fungi (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global characteristics and trends in research onFrontiers in microbiology · 2023Pooled it
- Kombucha-Mediated Silver Nanoparticles with Fungicidal Activity Against WHO-PriorityCurrent issues in molecular biology · 2026Article
- The Antimicrobial and Cytotoxic Activity of Green-Synthesized Silver Nanoparticle Extract of Marine Bacteria and Their 16S rRNA Identification and Characterization.Bioinorganic chemistry and applications · 2026Article
- Fungal Biofilm: An Overview of the Latest Nano-Strategies.Antibiotics (Basel, Switzerland) · 2025Review
- Novel approach to enhance antifungal properties via formation of wavy and Sharp microstructures composed of metal oxide nanoparticles and Cdots.Scientific reports · 2025Article
- Nanoparticles in the battle against Candida auris biofilms: current advances and future prospects.Drug delivery and translational research · 2025Review
- Innovative antifungal strategies to combat drug-resistantFrontiers in cellular and infection microbiology · 2025Review
- New Ground in Antifungal Discovery and Therapy for Invasive Fungal Infections: Innovations, Challenges, and Future Directions.Journal of fungi (Basel, Switzerland) · 2024Review
- Green Synthesis of Silver Oxide Nanoparticles fromNanomaterials (Basel, Switzerland) · 2024Article
- Phenotypic and Genotypic Characterization of Resistance and Virulence Markers inJournal of fungi (Basel, Switzerland) · 2024Article
- Current Perspectives of Antifungal Therapy: A Special Focus onJournal of fungi (Basel, Switzerland) · 2024Review
- Is Silver Addition to Scaffolds Based on Polycaprolactone Blended with Calcium Phosphates Able to InhibitInternational journal of molecular sciences · 2024Article
- Evaluation of flexural strength, impact strength, and surface microhardness of self-cured acrylic resin reinforced with silver-doped carbon nanotubes.BMC oral health · 2024Article
- Liposomal formulation of a new antifungal hybrid compound provides protection againstAntimicrobial agents and chemotherapy · 2024Article
- The Gordian Knot ofPathogens (Basel, Switzerland) · 2023Review
- Article
- Evaluation of compressive strength, surface microhardness, solubility and antimicrobial effect of glass ionomer dental cement reinforced with silver doped carbon nanotube fillers.BMC oral health · 2023Article
- Nanotechnology-Based Strategies to Combat Multidrug-ResistantPathogens (Basel, Switzerland) · 2023Review
- Article
- Synergistic Antifungal Interaction betweenAntibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida auris is a globally-emerging pathogen that is correlated to nosocomial infections and high mortality rates, causing major outbreaks in hospitals and serious public health concerns worldwide. This study investigated the antifungal activity of silver nanoparticles (AgNPs) on clinical isolates of C. auris. A total of eight clinical isolates were collected from blood, urine, ear swab, and groin. C. auris was confirmed by MALDI-TOF MS, and gene sequencing. All isolates confirmed as C. auris were subjected to antimicrobial agents, including amphotericin B, fluconazole, caspofungin, voriconazole, micafungin, and flucytosine. A serial dilution of a silver nanoparticles solution was prepared to test antifungal susceptibility testing under planktonic conditions. Moreover, an antibiofilm activity assay was determined using a colony-forming assay and a cell viability assay by a live−dead yeast kit. Significant antifungal and antibiofilm activity of AgNPs was detected against all isolates; MIC was <6.25 μg/mL, the range of MFC was from 6.25 to 12.5 μg/mL for all isolates, and the highest value of IC50 was 3.2 μg/mL. Silver nanomaterials could represent a possible antimicrobial agent to prevent outbreaks caused by C. auris infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.